Psychiatric Medications and Alcohol or Cannabis: What You Need to Know

Alcohol use disorder affects approximately 14.5 million Americans. Cannabis use has increased substantially as legalization has expanded — about 18% of U.S. adults reported using cannabis in the past year. Rates are disproportionately higher among people with anxiety, depression, ADHD, and other psychiatric conditions.

The reason is not complicated: both alcohol and cannabis temporarily reduce anxiety and emotional distress. Self-medication is a rational response to uncomfortable symptoms when other relief is not accessible or not working. The clinical problem is that while the short-term relief is real, chronic use of both substances undermines the conditions they are being used to treat — and can interfere with the medications meant to treat them.

There is also a disclosure problem. Studies consistently show that patients significantly underreport alcohol and cannabis use to their prescribers. This creates a gap in prescribing information that can result in underdosing, apparent treatment resistance, and missed safety risks. Disclosure is protective — not because it invites judgment, but because it leads to more accurate prescribing.

Alcohol interacts with psychiatric medications through multiple mechanisms: pharmacokinetic (how the medication moves through your body), pharmacodynamic (what the medication does), and through direct effects on the neurotransmitter systems that medications are targeting. The severity of interactions varies significantly by medication class.

SSRIs and SNRIs

SSRIs and SNRIs are generally considered among the safer combinations with occasional alcohol, but “safer” does not mean “no interaction.” Alcohol is a CNS depressant, and combining it with SSRIs/SNRIs can increase sedation beyond what either would produce alone. More clinically significant: alcohol is strongly depressogenic. Regular alcohol use directly counteracts what antidepressants are trying to accomplish — serotonin system stability. Increased impulsivity and emotional dysregulation are also documented effects of the combination, particularly at higher doses. The risk of serotonin syndrome from alcohol and SSRIs alone is low, but increases substantially when other serotonergic agents are involved.

Benzodiazepines — DANGEROUS

This is the combination that warrants the strongest warning. Both benzodiazepines and alcohol are CNS depressants that potentiate each other — combining them can produce respiratory depression, loss of consciousness, and death. This is not a theoretical risk; it is a documented cause of overdose deaths. There is no safe level of regular alcohol use on benzodiazepines, and acute intoxication while on a benzo should be treated as a medical emergency. If you are prescribed a benzodiazepine, this must be an explicit conversation with your prescriber.

Lithium

Alcohol causes dehydration and affects sodium balance. Lithium toxicity is driven by sodium depletion — when sodium drops, lithium is reabsorbed instead, and levels can spike dangerously. Alcohol also disrupts sleep, which is a major mood stabilizer in its own right, and directly destabilizes mood cycling in bipolar disorder. For people on lithium, regular alcohol use is particularly problematic — not just because of the toxicity pathway, but because it undermines the entire clinical goal of mood stabilization.

Antipsychotics

Antipsychotics (especially quetiapine, olanzapine, and clozapine) are already sedating. Alcohol amplifies this sedation, increasing the risk of falls, accidents, and impaired judgment beyond what either substance causes alone. Several antipsychotics also prolong the QTc interval; alcohol can further affect cardiac conduction. Clozapine and alcohol together carry particular risk of severe sedation and respiratory compromise.

Stimulants (ADHD medications)

Stimulants and alcohol create a paradoxical risk: the stimulant masks the subjective experience of intoxication — you may not feel drunk even when your BAC is elevated. This is associated with increased alcohol consumption and increased alcohol-related accidents and injuries. There is also cardiovascular stress: stimulants raise heart rate and blood pressure; alcohol initially lowers blood pressure and then raises it. The combination creates unpredictable cardiovascular strain.

MAOIs

MAOIs (phenelzine, tranylcypromine) have a well-documented dangerous interaction with tyramine — a compound found in aged cheeses, cured meats, fermented products, and certain wines and beers (particularly tap beer and Chianti). The interaction can cause hypertensive crisis — a sudden, severe spike in blood pressure that can cause stroke. People on MAOIs must follow a low-tyramine diet strictly, and this includes most alcoholic beverages. If you are on an MAOI, this needs explicit prescriber guidance on what is and is not safe.

Cannabis research has expanded significantly as legalization has progressed, but many of the clinical interactions are still being characterized. What we know is enough to warrant clear discussion.

CBD and drug interactions

Cannabidiol (CBD) is a potent inhibitor of CYP3A4 and CYP2C19 — two of the most important liver enzymes responsible for metabolizing psychiatric medications. When these enzymes are inhibited, medications that rely on them for clearance accumulate to higher levels than intended. This includes many SSRIs (such as citalopram, escitalopram, sertraline), SNRIs, and antipsychotics. Elevated drug levels mean both increased effect and increased side effects. If you are taking CBD — including over-the-counter CBD products — this is worth disclosing to your prescriber so levels and dosing can be calibrated accordingly.

THC and anxiety

The relationship between THC and anxiety is bidirectional and dose-dependent. Low doses of THC can reduce anxiety in some people short-term — this is the subjective relief that drives cannabis use for anxiety. But the clinical picture at regular use levels is consistently the opposite: chronic THC use increases baseline anxiety, reduces the brain's ability to regulate the fear response, and can worsen depression over time. Tolerance develops to the anxiolytic effect faster than to the anxiogenic effect, meaning the relief window narrows while the anxiety cost grows. For people on medications for anxiety or depression, this is directly working against the treatment goal.

THC and psychosis risk

The evidence for cannabis-induced psychosis in predisposed individuals is robust. High-THC cannabis products (above 10% THC, which describes most dispensary products today) are associated with significantly elevated risk of psychotic episodes in people with personal or family history of psychotic disorders, bipolar disorder, or other high-risk presentations. Daily use of high-potency cannabis is associated with a 5-fold increased risk of psychosis in some studies. For anyone on antipsychotics or mood stabilizers for a condition with psychotic features, this is not a theoretical risk.

ADHD and cannabis

Cannabis directly affects the dopaminergic system — the same system central to ADHD pathophysiology and the target of stimulant medications. Regular cannabis use impairs working memory, reduces motivation (amotivational syndrome), and dysregulates the dopamine system in ways that worsen the core deficits of ADHD. It also blunts the response to stimulant medications. People who use cannabis regularly while taking ADHD medication frequently find their medication is less effective than expected — this is a likely contributor.

Cannabis and antipsychotics

Cannabis — particularly high-THC products — can directly blunt the effectiveness of antipsychotic medications. THC activates dopamine release in the mesolimbic system; antipsychotics work by blocking dopamine receptors in that same system. These are directly opposing mechanisms. For people whose stability depends on antipsychotic medication, cannabis use is a significant risk factor for relapse.

The goal of this information is not to tell you never to drink or never to use cannabis. That is neither realistic nor, for many people, necessary. The goal is to give you the information you need to have an honest conversation with your prescriber and to understand the specific risks for your specific medications.

What to disclose: the frequency and amount of alcohol you consume, the frequency and amount of cannabis you use, and whether you are using CBD products (including oils, gummies, or topicals). “Occasional” means different things to different people — be as specific as you can. Your prescriber cannot make accurate clinical decisions without this information.

What questions to ask: Is my specific medication combination safe with occasional alcohol? Is my level of cannabis use likely to affect how well my medication works? If you find that you cannot comfortably reduce or stop using either substance, that is also information worth discussing — there are treatments for alcohol use disorder and cannabis use disorder that can work alongside psychiatric treatment.

Most interactions between substances and psychiatric medications are not acute emergencies — they are more subtle, chronic undermining of medication effectiveness and mental health stability. But some interactions can be serious and time-sensitive.

Watch for these signs and call your prescriber

• Your medication suddenly seems less effective after starting or increasing cannabis or alcohol use
• New or worsening side effects that coincide with cannabis or alcohol use (increased sedation, mood instability, cognitive changes)
• Increased anxiety or depression that seems worse despite medication — especially with regular cannabis use
• Mood cycling or instability in the context of alcohol use (particularly relevant for bipolar disorder and lithium)
• Unusual paranoia or perceptual changes after cannabis use, especially high-THC products

Go to the ER or call 911

• Respiratory difficulty or extreme sedation — especially if benzodiazepines and alcohol are involved; this is a potential overdose
• Severe, sudden headache or neck stiffness after drinking on an MAOI — possible hypertensive crisis
• Psychotic symptoms (hallucinations, severe paranoia, disorganized thinking) — especially if new or significantly worsened after cannabis use
• Loss of consciousness or unresponsiveness — any combination of substances
• Signs of lithium toxicity — coarse tremor, confusion, slurred speech, incoordination — particularly after heavy alcohol use with dehydration

These are questions worth asking directly. You deserve medication-specific answers, not generic warnings.

• “Is it safe to have occasional alcohol with my medication?” — Ask this specifically. The answer is genuinely different for SSRIs vs. benzodiazepines vs. lithium vs. antipsychotics. “Avoid alcohol” is not a clinical answer — ask for the specific risk and what “occasional” means in your context.
• “I use cannabis — what do I need to know?” — Disclose the frequency, approximate amount, and whether you use THC, CBD, or both. Ask specifically whether cannabis use might explain any apparent underperformance of your current medication.
• “Could my substance use be affecting how well my medication is working?” — If you feel like your medication is not working as well as it should, this is a clinically important question. The answer may require an honest conversation about use patterns.
• “What should I watch for that would mean I need to call you or go to the ER?” — Ask this before you need it. The answer will vary based on which medications you are on.
• “Are there safer alternatives for what I'm using the alcohol or cannabis for?” — If you are primarily using substances to manage anxiety, sleep, or mood, that is a signal that your current treatment plan may have a gap that is worth addressing directly.